Xanthoxyletin blocks the RANK/RANKL signaling pathway to suppress the growth of human pancreatic cancer cells

1P. Rawla, T. Sunkara and V. Gaduputi, Epidemiology of pancreatic cancer: Global trends, etiology and risk factors, World J. Oncol. 10(1) (2019) 10–27; https://doi.org/10.14740/wjon1166Search in Google Scholar

2W. Wu, X. He, L. Yang, Q. Wang, X. Bian, J. Ye, Y. Li and L. Li, Rising trends in pancreatic cancer incidence and mortality in 2000-2014, Clin Epidemiol. 10 (2018) 789–797; https://doi.org/10.2147/CLEP.S160018Search in Google Scholar

3M. Ilic and I. Ilic, Epidemiology of pancreatic cancer, World J. Gastroenterol. 22(44) (2016) 9694–9705; https://doi.org/10.3748/wjg.v22.i44.9694Search in Google Scholar

4J. P. Neoptolemos, J. Kleeff, P. Michl, E. Costello, W. Greenhalf and D. H. Palmer, Therapeutic developments in pancreatic cancer: current and future perspectives, Nat. Rev. Gastroenterol. Hepatol. 15(6) (2018) 333–348; https://doi.org/10.1038/s41575-018-0005-xSearch in Google Scholar

5H. L. Kindler, A glimmer of hope for pancreatic cancer, N. Engl. J. Med. 379(25) (2018) 2463–2464; https://doi.org/10.1056/NEJMe1813684Search in Google Scholar

6N. Wang and Y. Feng, Elaborating the role of natural products-induced autophagy in cancer treatment: achievements and artifacts in the state of the art, Biomed. Res. Int. 2015 (2015) Article ID 934207 (15 pages); https://doi.org/10.1155/2015/934207Search in Google Scholar

7S. K. Saha and A. R. Khuda-Bukhsh, Molecular approaches towards development of purified natural products and their structurally known derivatives as efficient anti-cancer drugs: current trends, Eur. J. Pharmacol. 714(1-3) (2013) 239–248; https://doi.org/10.1016/j.ejphar.2013.06.009Search in Google Scholar

8I. Lohse, E. Wildermuth and S. P. Brothers, Naturally occurring compounds as pancreatic cancer therapeutics, Oncotarget 9(83) (2018) 35448–35457; https://doi.org/10.18632/oncotarget.26234Search in Google Scholar

9E. Kupeli Akkol, Y. Genc, B. Karpuz, E. Sobarzo-Sanchez and R. Capasso, Coumarins and coumarin-related compounds in pharmacotherapy of cancer, Cancers (Basel) 12(7) (2020) Article ID 1959; https://doi.org/10.3390/cancers12071959Search in Google Scholar

10A. Rasul, M. Khan, B. Yu, T. Ma and H. Yang, Xanthoxyletin, a coumarin induces S phase arrest and apoptosis in human gastric adenocarcinoma SGC-7901 cells, Asian Pac. J. Cancer Prev. 12(5) (2011) 1219–1223.Search in Google Scholar

11N. Renema, B. Navet, M. F. Heymann, F. Lezot and D. Heymann, RANK-RANKL signaling in cancer, Biosci. Rep. (2016) 36(4) Article ID e00366 (17 pages); https://doi.org/10.1042/BSR20160150Search in Google Scholar

12A. F. de Groot, N. M. Appelman-Dijkstra, S. H. van der Burg and J. R. Kroep, The antitumor effect of RANKL inhibition in malignant solid tumors – A systematic review, Cancer Treat. Rev. (2018) 62 18–28; https://doi.org/10.1016/j.ctrv.2017.10.010Search in Google Scholar

13M. Palafox, I. Ferrer, P. Pellegrini, S. Vila, S. Hernadez-Ortega, A. Urricoechea, F. Climent, M. T. Soler, P. Munoz, F. Vinals, M. Tometsko, D. Branstetter, W. C. Dougall and E. Gonzalez-Suarez, RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis, Cancer Res. (2012) 72(11) 2678–2688; https://doi.org/10.1158/0008-5472.CAN-12-0044Search in Google Scholar

14P. Pellegrini, A. Cordero, M. I. Gallego, W. C. Dougall, P. Munoz, M. A. Pujana and E. Gonzalez-Suarez, Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis, Stem Cells (2013) 31(9) 1954–1965; https://doi.org/10.1002/stem.1454Search in Google Scholar

15S. J. Chanock, The paradox of mutations and cancer, Science 362(6417) (2018) 893–894; https://doi.org/10.1126/science.aav5697Search in Google Scholar

16F. Sanchez-Vega, M. Mina, J. Armenia, W. K. Chatila, A. Luna, K. C. La, S. Dimitriadoy, D. L. Liu, H. S. Kantheti, S. Saghafinia, D. Chakravarty, F. Daian, Q. Gao, M. H. Bailey, W. W. Liang, S.M. Foltz, I. Shmulevich, L. Ding, Z. Heins, A. Ochoa, B. Gross, J. Gao, H. Zhang, R. Kundra, C. Kandoth, I. Bahceci, L. Dervishi, U. Dogrusoz, W. Zhou, H. Shen, P.W. Laird, G. P. Way, C.S. Greene, H. Liang, Y. Xiao, C. Wang, A. Iavarone, A. H. Berger, T. G. Bivona, A. J. Lazar, G.D. Hammer, T. Giordano, L. N. Kwong, G. McArthur, C. Huang, A. D. Tward, M. J. Frederick, F. McCormick, M. Meyerson, E. M. Van Allen, A. D. Cherniack, G. Ciriello, C. Sander and N. Schultz, Oncogenic signaling pathways in the cancer genome atlas, Cell 173(2) (2018) 321–337; https://doi.org/10.1016/j.cell.2018.03.035Search in Google Scholar

17N. Renema, B. Navet, M. F. Heymann, F. Lezot and D. Heymann, RANK-RANKL signalling in cancer, Biosci. Rep. 36(4) (2016) Article ID e00366 (17 pages); https://doi.org/10.1042/BSR20160150Search in Google Scholar

18S. Rao, S. J. F. Cronin, V. Sigl and J. M. Penninger, RANKL and RANK: From mammalian physiology to cancer treatment, Trends Cell Biol. 28(3) (2018) 213–223; https://doi.org/10.1016/j.tcb.2017.11.001Search in Google Scholar

19S. Peters, P. Clezardin, I. Marquez-Rodas, D. Niepel and C. Gedye, The RANK-RANKL axis: an opportunity for drug repurposing in cancer? Clin. Transl. Oncol. 21(8) (2019) 977–991; https://doi.org/10.1007/s12094-018-02023-5Search in Google Scholar

20P. A. van Dam, Y. Verhoeven, X. B. Trinh, A. Wouters, F. Lardon, H. Prenen, E. Smits, M. Baldewijns and M. Lammens, RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment, Crit. Rev. Oncol. Hematol. 133 (2019) 85–91; https://doi.org/10.1016/j.critrevonc.2018.10.011Search in Google Scholar

21Q. Wen, K. Luo, H. Huang, W. Liao and H. Yang, Xanthoxyletin inhibits proliferation of human oral squamous carcinoma cells and induces apoptosis, autophagy, and cell cycle arrest by modulation of the MEK/ERK signaling pathway, Med. Sci. Monit. 25 (2019) 8025–8033; https://doi.org/10.12659/MSM.911697Search in Google Scholar

22A. Rasul, M. Khan, B. Yu, T. Ma and H. Yang, Xanthoxyletin, a coumarin induces S phase arrest and apoptosis in human gastric adenocarcinoma SGC-7901 cells, Asian Pac. J. Cancer Prev. (2011) 12(5)1219–1223.Search in Google Scholar

23E. Gonzalez-Suarez and A. Sanz-Moreno, RANK as a therapeutic target in cancer, FEBS J 283(11) (2016) 2018–2033; https://doi.org/10.1111/febs.13645Search in Google Scholar

24A. von dem Knesebeck, J. Felsberg, A. Waha, W. Hartmann, B. Scheffler, M. Glas, J. Hammes, T. Mikeska, P. S. Yan, E. Endl and M. Simon, RANK (TNFRSF11A) is epigenetically inactivated and induces apoptosis in gliomas, Neoplasia (2012) 14(6) 526–534; https://doi.org/10.1596/neo.12360Search in Google Scholar

25M. Sisay, G. Mengistu and D. Edessa, The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy, OncoTargets Ther. (2017) 10 3801–3810; https://doi.org/10.2147/OTT.S135867Search in Google Scholar